Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RADICAL trial: what clinicians have said so far
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
- NCT04071223 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on RADICAL yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RADICAL so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Advanced Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Collecting Duct Carcinoma; Kidney Medullary Carcinoma; Metastatic Malignant Neoplasm in the Bone; Papillary Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8; Unclassified Renal Cell Carcinoma
- Interventions
- Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Questionnaire Administration; Radium Ra 223 Dichloride
- Arms
- Arm A (radium Ra 223 dichloride, cabozantinib s-malate) · Experimental
- Arm B (cabozantinib s-malate) · Active comparator
- Enrollment
- 98
- Primary outcomes
- Symptomatic skeletal event (SSE)-free survival (FS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jul 29, 2020
- Primary completion
- Jul 27, 2026
- Results posted
- No
- Registry record
- NCT04071223 · updated Sep 28, 2026
Publications
linked from the registry- McKay RR, Ballman KV, Atherton PJ, Ajmera A, Al Baghdadi T, Baumann BC, Beltran H, Berg S, Chen RC, Choudhury AD, Cole S, Jacene HA, Lang JM, Kilari D, Kwok Y, McGregor B, Morris MJ, Parikh M, Swami U, Tan A, Yang YA, Zhang T, Galsky M, Rosenberg J, George D, Choueiri TK. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). J Clin Oncol. 2026 Aug 20;44(24):2341-2352. doi: 10.1200/JCO-26-01135. Epub 2026 Jul 27. PubMed 42507969
- Bade RM, Schehr JL, Emamekhoo H, Gibbs BK, Rodems TS, Mannino MC, Desotelle JA, Heninger E, Stahlfeld CN, Sperger JM, Singh A, Wolfe SK, Niles DJ, Arafat W, Steinharter JA, Jason Abel E, Beebe DJ, Wei XX, McKay RR, Choueri TK, Lang JM. Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. Mol Oncol. 2021 Sep;15(9):2330-2344. doi: 10.1002/1878-0261.12931. Epub 2021 Mar 3. PubMed 33604999